PAVmed (NASDAQ:PAVM) and Novocure (NASDAQ:NVCR) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, analyst recommendations, profitability, institutional ownership and risk.

Analyst Ratings

This is a breakdown of current ratings and price targets for PAVmed and Novocure, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PAVmed 0 0 1 0 3.00
Novocure 0 3 4 0 2.57

PAVmed currently has a consensus target price of $3.00, indicating a potential upside of 180.37%. Novocure has a consensus target price of $48.57, indicating a potential downside of 8.20%. Given PAVmed’s stronger consensus rating and higher probable upside, equities analysts clearly believe PAVmed is more favorable than Novocure.

Valuation and Earnings

This table compares PAVmed and Novocure’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
PAVmed N/A N/A -$17.97 million N/A N/A
Novocure $248.07 million 20.43 -$63.56 million ($0.69) -76.68

PAVmed has higher earnings, but lower revenue than Novocure.


This table compares PAVmed and Novocure’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
PAVmed N/A -9,072.85% -119.06%
Novocure -20.42% -47.23% -16.47%

Risk & Volatility

PAVmed has a beta of 0.25, meaning that its stock price is 75% less volatile than the S&P 500. Comparatively, Novocure has a beta of 3.04, meaning that its stock price is 204% more volatile than the S&P 500.

Insider & Institutional Ownership

2.0% of PAVmed shares are owned by institutional investors. Comparatively, 61.8% of Novocure shares are owned by institutional investors. 29.2% of PAVmed shares are owned by insiders. Comparatively, 5.6% of Novocure shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.


Novocure beats PAVmed on 6 of the 11 factors compared between the two stocks.

PAVmed Company Profile

PAVmed Inc. operates as a medical device company in the United States. The company's lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; EsoCheck, an non-invasive cell collection device and DNA biomarkers to detect esophageal cancer precursor; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube. Its product pipeline also comprises NextCath, a self-anchoring catheter; NextFlo, a disposable infusion system; and Caldus, a disposable tissue ablation device. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was founded in 2014 and is based in New York, New York.

Novocure Company Profile

Novocure Ltd. is global oncology company, which engages in the development and commercialization of its innovative therapy. It focuses on the commercial adoption of Optune, and its Tumor Treating Fields delivery system, for the treatment of glioblastoma (GBM), and to advance programs testing the efficacy and safety of Optune in multiple solid tumor indications through clinical pipeline. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with's FREE daily email newsletter.